You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Multiple Sclerosis Drug Fingolimod Receives New Safety Warnings Related to Cardiovascular Risk

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000418919.07483.75
Drug Watch
Abstract

* Fingolimod (Gilenya), a drug used in the treatment of relapsing forms of multiple sclerosis, has new labeled warnings related to the potential for serious and potentially life-threatening bradycardia.

* The risk of bradycardia is heightened in the first six hours after the initial dose, as well as between 12 and 20 hours after the first dose.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.